Cancer-associated Macrophage-like Cells in Patients with Non-metastatic Adenocarcinoma of the Esophagus – Cytomorphological Heterogeneity

Clara Braun, Claudia Schmoor, Sylvia Timme-Bronsert, Stefan Fichtner-Feigl, Jens Hoeppner, Birte Kulemann, Jasmina Kuvendjiska
DOI: 10.7150/jca.82668
PMID: 37497409

Abstract

Introduction: Esophageal adenocarcinoma (EAC) often recurs systemically despite therapy with a curative aim. New diagnostic and therapeutic approaches are urgently needed. A promising field is liquid biopsy, meaning the investigation of tumor-associated cells in the peripheral blood, for example cancer-associated macrophage-like cells (CAML). The aim of this multicentric study was to investigate the presence and cytomorphological appearance of CAML in patients with non-metastatic and operable esophageal cancer.Methods: Blood samples from 252 patients with locally advanced EAC were obtained before starting curative treatment including surgery, and then processed using ScreenCell® filtration devices. Cytological analysis was performed via May-Grünwald-Giemsa staining. CAML were defined by their morphological characteristics. We also performed immunofluorescence staining with the mesenchymal marker vimentin on a subset of our study cohort.Results: We detected cytomorphologically heterogeneous CAML in 31.8% (n=80) patients. Their presence and cell count did not correlate significantly with pretherapeutic cTNM. Even in patients with small tumors and no lymph-node infiltration, cell counts were high. CAML showed heterogenous staining patterns for vimentin.Conclusion: This is one of the first studies demonstrating the presence and phenotype of CAML in a uniquely broad cohort of EAC patients. As they are believed to be representatives of the inflammatory tumor microenvironment shed into the bloodstream, their presence in non-metastatic EAC is a promising finding.

Keywords

cancer-associated macrophage-like cell, CAML, esophageal adenocarcinoma, cytopathology, liquid biopsy, liquid biomarker

Stay informed about our publications

Lastest publications

Isolation and profiling of single circulating tumor cells in myeloma: a new workflow for liquid biopsies.

Liquid biopsy in breast cancer: Redefining precision medicine

Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical Applications

A project on circulating tumor cells?

From isolation to downstream analysis, ScreenCell® adapts to each step.

Follow ScreenCell on